[1] Sessink, P. J. M., & Bos, R. P. (1999). Drugs hazardous to healthcare workers. Evaluation of methods for monitoring occupational exposure to cytostatic drugs. Drug Safety, 20(4), 347–359.
[2] Kiffmeyer, T. K., Tuerk, J., Hahn, M., Stuetzer, H., Hadtstein, C., Heinemann, A., & Eickmann, U. (2013). Application and assessment of a regular environmental monitoring of the antineoplastic drug contamination level in pharmacies-the MEWIP project. Annals of Occupational Hygiene, 57(4), 444–455.
[3] Kromhout, H., Hoek, F., Uitterhoeve, R., Huijbers, R., Overmars, R. F., Anzion, R., & Vermeulen, R. (2000). Postulating a dermal pathway for exposure to anti-neoplastic drugs among hospital workers. Applying a conceptual model to the results of three workplace surveys. The Annals of Occupational Hygiene, 44(7), 551–560.
[4] Connor, T. H., DeBord, D. G., Lees, P. S. J. P., Krieg, E. F., Rogers, B., Escalante, C. P., McDiarmid, M. (2010). Evaluation of antineoplastic drug exposure of health care workers at three university-based US cancer centers. Journal of Occupational and Environmental Medicine / American College of Occupational and Environmental Medicine, 52(10), 1019–1027.
[5] Acampora, A., Castiglia, L., Miraglia, N., Pieri, M., Soave, C., Liotti, F., & Sannolo, N. (2005). A case study: Surface contamination of cyclophosphamide due to working practices and cleaning procedures in two Italian hospitals. Annals of Occupational Hygiene, 49(7), 611–618.
[6] NIOSH, National Institute for Occupational Safety and Health (2004). Preventing occupational exposures to antineoplastic and other harzardous drugs in health care settings (Internet). American: NIOSH; 2004 (cited 2007 Mai 27). Available from:http://www.cdc.gov/niosh/docs/2004-165/;
[7] Suspiro, A., & Prista, J. (2012). Exposição ocupacional a citostáticos e efeitos sobre a saúde. Revista Portuguesa de Saude Publica, 30(1), 76–88.
[8] Infarmed, Medicamentos antineoplásicos e imunomoduladores. http://www.infarmed.pt/formulario/navegacao.php?paiid=266. Accessed online in 2014/04/18.
[9] Schierl, R., Böhlandt, A., & Nowak, D. (2009). Guidance values for surface monitoring of antineoplastic drugs in german pharmacies. Annals of Occupational Hygiene, 53(7), 703–711.
[10] Kopjar, N. Garaj-Vrhovac, V. Kasuba, V. Rozgaj, R. Ramic, S. Pavlica, V. Zeljezic, D. (2009). Assessment of genotoxic risk in Croation health care workers occupationally exposed to cytotoxic drugs: A multi-biomaker approach. ScienceDirect revista, pp. 414-431.
[11] Sottani, C., Porro, B., Imbriani, M., & Minoia, C. (2012). Occupational exposure to antineoplastic drugs in four Italian health care settings. Toxicology Letters, 213(1), 107–115.
[12] Silva, J. (2011). Manipulação de citostáticos num hospital: estudo do impacto sobre a contaminação do ambiente ocupacional. Master thesis, Minho University.
[13] Moher, D., Liberati, Tetzlaff, J., Altman, D. G., & Grp, P. (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement (Reprinted from Annals of Internal Medicine). Physical Therapy, 89(9), 873–880.
[14] Brouwers, E. E. M., Huitema. D. R., Bakker, E. N., Douma, J. W., Schimmel, K. J. M., van Weringh, G., … Beijnen, J. H. (2007). Monitoring of platinum surface contamination in seven Dutch hospital pharmacies using inductively coupled plasma mass spectrometry. International Archives of Occupational and Environmental Health, 80(8), 689–699.
[15] Schmaus, G., Schierl, R., & Funck, S. (2002). Monitoring surface contamination by antineoplastic drugs using gas chromatography–mass spectrometry and voltammetry. American Journal of Health-System Pharmacy, 59, 956–961.
[16] Yoshida, J., Tei, G., Mochizuki, C., Masu, Y., Koda, S., & Kumagai, S. (2009). Use of a closed system device to reduce occupational contamination and exposure to antineoplastic drugs in the hospital work environment. Annals of Occupational Hygiene, 53(2), 153–160.
[17] Connor, T. H., Anderson, R. W., Sessink, P. J., Broadfield, L., & Power, L. A. (1999). Surface contamination with antineoplastic agents in six cancer treatment centers in Canada and the United States. American Journal of Health-System Pharmacy: AJHP: Official Journal of the American Society of Health-System Pharmacists, 56(14), 1427–1432. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/10428450.
[18] Crauste-Manciet, S., Sessink, P. J. M., Ferrari, S., Jomier, J. Y., & Brossard, D. (2005). Environmental contamination with cytotoxic drugs in healthcare using positive air pressure isolators. Annals of Occupational Hygiene, 49(7), 619–628.
[19] Viegas, S., Pádua, M., Veiga, A. C., Carolino, E., & Gomes, M. (2014). Antineoplastic drugs contamination of workplace surfaces in two Portuguese hospitals. Environmental Monitoring and Assessment, 186(11), 7807–7818.
[20] Berruyer, M., Tanguay, C., Caron, N. J., Lefebvre, M., & Bussières, J. F. (2015). Multicenter study of environmental contamination with antineoplastic drugs in 36 Canadian hospitals: a 2013 follow-up study. Journal of Occupational and Environmental Hygiene, 12(2), 87–94. http://doi.org/10.1080/15459624.2014.949725
[21] Odraska, P., Dolezalova, L., Kuta, J., Oravec, M., Piler, P., Synek, S., & Blaha, L. (2014). Association of surface contamination by antineoplastic drugs with different working conditions in hospital pharmacies. Archives of Environmental & Occupational Health, 69(3), 148–58.
[22] Kopp, B., Schierl, R., & Nowak, D. (2013). Evaluation of working practices and surface contamination with antineoplastic drugs in outpatient oncology health care settings. International Archives of Occupational and Environmental Health, 86(1), 47–55.
[23] Hon, C.-Y., Teschke, K., Chu, W., Demers, P., & Venners, S. (2013). Antineoplastic drug contamination of surfaces throughout the hospital medication system in Canadian hospitals. Journal of Occupational and Environmental Hygiene, 10(7), 374–83.
[24] Hon, C.-Y., Teschke, K., Chua, P., Venners, S., & Nakashima, L. (2011). Occupational Exposure to Antineoplastic Drugs: Identification of Job Categories Potentially Exposed throughout the Hospital Medication System. Safety and Health at Work, 2(3), 273.
[25] Dal Bello, F., Santoro, V., Scarpino, V., Martano, C., Aigotti, R., Chiappa, A., … Medana, C. (2016). Antineoplastic drugs determination by HPLC-HRMSn to monitor occupational exposure. Drug Testing and Analysis, 8(7), 730–737.
[26] Hedmer, M., Tinnerberg, H., Axmon, & Jönsson, B. G. (2008). Environmental and biological monitoring of antineoplastic drugs in four workplaces in a Swedish hospital. International Archives of Occupational and Environmental Health, 81(7), 899–911.